白蛋白与纤维蛋白原的比值预测弥漫大B细胞淋巴瘤患者预后的价值
《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]
- 期数:
- 2023年14期
- 页码:
- 2695-2699
- 栏目:
- 论著（血液系统肿瘤）
- 出版日期:
- 2023-06-12
文章信息/Info
- Title:
- Prognostic value of albumin to fibrinogen ratio in diffuse large B-cell lymphoma
- Author(s):
- SHI Xuebing1; WANG Lu2; DENG Wenxia1; WU Jing1
- 1.Department of Medical Oncology,Tongling People's Hospital,Anhui Tongling 244000,China;2.Department of Medical Oncology,Yijishan Hospital of Wannan Medical College,Anhui Wuhu 241000,China.
- Keywords:
- albumin; fibrinogen; diffuse large B-cell lymphoma; prognosis
- 分类号:
- R733.4
- DOI:
- 10.3969/j.issn.1672-4992.2023.14.023
- 文献标识码:
- A
- 摘要:
- 目的：探讨血清白蛋白（albumin，ALB）与血浆纤维蛋白原（fibrinogen，FIB）的比值（ALB to FIB ratio，AFR）对弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL)患者预后的影响。方法:选择我院2015-04-17至2022-03-18确诊的DLBCL病例59例，收集所有患者首次化疗前1周内的血清ALB值、血浆FIB值，计算出AFR。应用生存分析研究AFR对DLBCL患者无进展生存率(progression free survival，PFS)的影响。应用受试者工作特征曲线(receiver operating characteristic curve,ROC)下的面积（area under the ROC curve,AUC）来评估各模型对DLBCL患者预后预测能力的大小。结果:AFR范围3.87～20.13，中位数11.16。AFR与IPI、Ann Arbor分期、结外侵犯数以及B症状密切相关。Kaplan-Meier生存分析提示，AFR增高时，DLBCL患者的PFS显著提高（P＜0.001），2年累积PFS与低AFR组患者相比提高了73.0%。Cox单因素分析提示，低AFR的DLBCL患者发生肿瘤进展或死亡的风险显著增加（P=0.002）；多因素分析提示，AFR是影响DLBCL患者PFS的独立因素（P=0.004）。国际预后指数（international prognostic index，IPI）和IPI联合AFR两种模型判断DLBCL患者PFS的AUC值分别为0.778（95%CI 0.659～0.897,P＜0.001）和0.829（95%CI 0.723～0.935,P＜0.001）。结论:AFR是判断DLBCL患者PFS的独立预测因子，IPI联合AFR能够更好地判断DLBCL患者的预后。
- Abstract:
- Objective:To explore the effect of serum albumin(ALB) to plasma fibrinogen（FIB）ratio（AFR）on the prognosis of patients with diffuse large B-cell lymphoma（DLBCL）.Methods:Fifty nine cases of DLBCL diagnosed in our hospital from April 17th,2015 to March 18th,2022 were selected.The serum ALB and plasma FIB of all patients within 1 week before the first chemotherapy were collected to calculate the AFR.The impact of AFR on the progression free survival (PFS) of patients with DLBCL was evaluated by survival analysis.The area under the receiver operating characteristic (ROC) curve (AUC) was used to assess the capability of each model to predict the prognosis of DLBCL patients.Results:The range of AFR was from 3.87 to 20.13,with a median of 11.16.AFR was closely related to IPI,Ann Arbor staging,extranodal invasion and B symptoms.Kaplan-Meier survival analysis showed that the PFS of DLBCL patients increased significantly when AFR increased（P＜0.001）.Compared with low AFR group,the 2-year PFS of high AFR group increased by 73.0%.Cox univariate analysis showed that low AFR was a risk factor for PFS of DLBCL patients（P=0.002）.Multivariate analysis indicated that AFR was an independent factor affecting PFS of DLBCL patients（P=0.004）.The AUC values of international prognostic index (IPI) and IPI combined with AFR in predicting PFS of DLBCL patients were 0.778（95%CI 0.659～0.897,P＜0.001）and 0.829（95%CI 0.723～0.935,P＜0.001）respectively.Conclusion:AFR is an independent predictor of PFS in patients with DLBCL.IPI combined with AFR can better evaluate the prognosis of patients.
参考文献/References
［1］MAHMOOD H,HABIB M,ASLAM W,et al.Clinicopathological spectrum of diffuse large B cell lymphoma:a study targeting population yet unexplored in Pakistan［J］.BMC Res Notes,2021,14(1):354.
［2］LIU Y,BARTA SK.Diffuse large B-cell lymphoma:2019 update on diagnosis,risk stratification,and treatment［J］.Am J Hematol,2019,94(5):604-616.
［3］NUVVULA S,DAHIYA S,PATEL SA.The novel therapeutic landscape for relapsed/refractory diffuse large B cell lymphoma［J］.Clin Lymphoma Myeloma Leuk,2022,22(6):362-372.
［4］BELTRAN BE,VILLELA L,TORRES MA,et al.A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio in patients with diffuse large B-cell lymphoma:A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)［J］.Clin Lymphoma Myeloma Leuk,2020,20(10):637-646.
［5］BENTOL，DIAZ-LOPEZ A，BARRANCO G,et al.New prognosis score including absolute lymphocyte/monocyte ratio,red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP:Spanish Lymphoma Group Experience (GELTAMO)［J］.Br J Haematol,2020,188(6):888-897.
［6］GAO F,HU J,ZHANG J,et al.Prognostic value of peripheral blood lymphocyte/monocyte ratio in lymphoma［J］.J Cancer,2021,12(12):3407-3417.
［7］KEANE C,TOBIN J,TALAULIKAR D,et al.A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival［J］.Oncotarget,2018,9(34):23620-23627.
［8］RUPPERT AS,DIXON JG,SALLES G,et al.International prognostic indices in diffuse large B-cell lymphoma:a comparison of IPI,R-IPI,and NCCN-IPI［J］.Blood,2020,135(23):2041-2048.
［9］SUN F,ZHU J,LU S,et al.An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era［J］.BMC Cancer,2018,18(1):5.
［10］KANEKO H,SHIMURA K,YOSHIDA M,et al.Serum albumin levels strongly predict survival outcome of elderly patients with diffuse large B-cell lymphoma treated with rituximab-combined chemotherapy［J］.Int J Hematol Oncol Stem Cell Res,2022,16(1):1-8.
［11］WEI Y,WEI X,HUANG W,et al.Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma［J］.Int J Hematol,2020,111(5):681-685.
［12］GRADEL KO,LARSEN TS,FREDERIKSEN H,et al.Impact of C-reactive protein and albumin levels on short,medium,and long term mortality in patients with diffuse large B-cell lymphoma［J］.Ann Med,2022,54(1):713-722.
［13］VLATKA P,MARKO L,STEFAN M,et al.The hemoglobin,albumin,lymphocyte,and platelet (HALP) score is a novel prognostic factor for patients with diffuse large B-cell lymphoma［J］.J Cancer Res Ther,2022,18(3):725-732.
［14］SHEN Z,HU L,ZHANG S,et al.Visceral fat area and albumin based nutrition-related prognostic index model could better stratify the prognosis of diffuse large B-cell lymphoma in rituximab era［J］.Front Nutr,2022,9:981433.
［15］OZTURK E,ELIBOL T,KILICASLAN E,et al.Prognostic nutritional index predicts early mortality in diffuse large B-cell lymphoma［J］.Medeni Med J,2022,37(1):85-91.
［16］TROPPAN KT,MELCHARDT T,WENZL K,et al.The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma［J］.J Clin Pathol,2016,69(4):326-330.
［17］NIU JY,TIAN T,ZHU HY,et al.Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma［J］.Ann Hematol,2018,97(10):1841-1849.
［18］王鑫,吴重阳,曾鹏云,等.红细胞分布宽度和纤维蛋白原水平对判断弥漫大B细胞淋巴瘤患者疗效及预后的价值［J］.中国实验血液学杂志,2020,28(1):153-159.
WANG X,WU CY,ZENG PY,et al.Value of red blood cell distribution width and fibrinogen level for evaluation of the therapeutic efficacy and prognosis in patients with diffuse large B-cell lymphoma［J］.The Chinese Journal of Experimental Hematology,2020,28(1):153-159.
备注/Memo
- 备注/Memo:
- -
